Northern Lights Advisors’s Tenaya Therapeutics TNYA Stock Holding History

Northern Lights Advisors’s Portfolio TNYA Stock Details TNYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.1K	Hold	14,953	–	–	0.01%	72
2026 Q1	$10.4K	Hold	14,953	–	–	0.01%	57
2025 Q4	$10.6K	Buy	+14,953	New	+$20.3K	0.01%	53

Other funds holding TNYA

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

BGM

Burkehill Global Management New York $2.77B AUM 65.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Lights Advisors's TNYA Position: Q2 2026 in Review

Northern Lights Advisors held its Tenaya Therapeutics (TNYA) position steady in Q2 2026 at 14,953 shares worth $11.1K. The position accounts for 0.01% of the portfolio, ranked #72.

Northern Lights Advisors first reported a position in TNYA in Q4 2025 and has held it in 3 quarters since. 101 funds tracked by Wall St. Rank hold TNYA as of Q2 2026.

Northern Lights Advisors held 14,953 shares of Tenaya Therapeutics worth $11.1K as of Q2 2026.
Northern Lights Advisors left its Tenaya Therapeutics share count unchanged in Q2 2026.
Tenaya Therapeutics made up 0.01% of Northern Lights Advisors's portfolio in Q2 2026, its #72 holding.
Northern Lights Advisors first reported a position in Tenaya Therapeutics in Q4 2025 and has held it in 3 quarters since.
101 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2026.

Based on Northern Lights Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.